Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

Open access
Burd, Amy, Levine, Ross L., Ruppert, Amy S., Mims, Alice S., Borate, Uma, Stein, Eytan M., Patel, Prapti, Baer, Maria R., Stock, Wendy, Deininger, Michael, Blum, William, Schiller, Gary, Olin, Rebecca, Litzow, Mark, Foran, James, Lin, Tara L., Ball, Brian, Boyiadzis, Michael, Traer, Elie, Odenike, Olatoyosi, Arellano, Martha, Walker, Alison, Duong, Vu. H., Kovacsovics, Tibor, Collins, Robert, Shoben, Abigail B., Heerema, Nyla A., Foster, Matthew C., Vergilio, Jo-Anne, Brennan, Tim, Vietz, Christine, Severson, Eric, Miller, Molly, Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley, Chen, Timothy, Stefanos, Mona, Druker, Brian, Byrd, John C. · 2020 · Nature Medicine

Abstract

Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults, AML confers an adverse outcome1,2. AML originates from a dominant mutation, then acquires collaborative transformative mutations leading to myeloid transformation and clinical/biological heterogeneity. Currently, AML treatment is initiated rapidly, precluding the ability to consider the mutational profile of a patient’s leukemia for treatment decisions. Untreated patients with AML ≥ 60 years were prospectively enrolled on the ongoing Beat AML trial (ClinicalTrials.gov NCT03013998), which aims to provide cytogenetic and mutational data within 7 days (d) from sample receipt and before treatment selection, followed by treatment assignment to a sub-study based on the dominant clone. A total of 487 patients with suspected AML were enrolled; 395 were eligible. Median age was 72 years (range 60–92 years; 38% ≥75 years); 374 patients (94.7%) had genetic and cytogenetic analysis completed within 7 d and were centrally assigned to a Beat AML sub-study; 224 (56.7%) were enrolled on a Beat AML sub-study. The remaining 171 patients elected standard of care (SOC) (103), investigational therapy (28) or palliative care (40); 9 died before treatment assignment. Demographic, laboratory and molecular characteristics were not significantly different between patients on the Beat AML sub-studies and those receiving SOC (induction with cytarabine + daunorubicin (7 + 3 or equivalent) or hypomethylation agent). Thirty-day mortality was less frequent and overall survival was significantly longer for patients enrolled on the Beat AML sub-studies versus those who elected SOC. A precision medicine therapy strategy in AML is feasible within 7 d, allowing patients and physicians to rapidly incorporate genomic data into treatment decisions without increasing early death or adversely impacting overall survival. Preliminary results from the Beat AML umbrella trial demonstrates the feasibility and efficacy of applying prospective genomic profiling for matching newly diagnosed patients with AML with targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-1089-8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 185

Metadata

Authors
Burd, A., Levine, R. L., Ruppert, A. S., Mims, A. S., Borate, U., Stein, E. M., Patel, P., Baer, M. R., Stock, W., Deininger, M., Blum, W., Schiller, G., Olin, R., Litzow, M., Foran, J., Lin, T. L., Ball, B., Boyiadzis, M., Traer, E., Odenike, O., Arellano, M., Walker, A., Duong, V. H., Kovacsovics, T., Collins, R., Shoben, A. B., Heerema, N. A., Foster, M. C., Vergilio, J.-A., Brennan, T., Vietz, C., Severson, E., Miller, M., Rosenberg, L., Marcus, S., Yocum, A., Chen, T., Stefanos, M., Druker, B., & Byrd, J. C.
Venue
Nature Medicine
Published
2020-10-26
Volume
26
Issue
12
Pages
1852-1858
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3094566369
Cited by
185
References
9
FWCI
14.31
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. https://app.cochat.ai/papers/10.1038/s41591-020-1089-8
The paper
Burd, A., Levine, R. L., Ruppert, A. S., Mims, A. S., Borate, U., Stein, E. M., Patel, P., Baer, M. R., Stock, W., Deininger, M., Blum, W., Schiller, G., Olin, R., Litzow, M., Foran, J., Lin, T. L., Ball, B., Boyiadzis, M., Traer, E., . . . Byrd, J. C. (2020). Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature Medicine. https://doi.org/10.1038/s41591-020-1089-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.